Here’s a brief summary of the key developments impacting pharmaceutical and medical device companies in the EU:
-
EU Pharma Package: The final texts for the new EU Pharma Package have been published, focusing on revising pharmaceutical laws to encourage innovation while also fostering generics. Key measures include shorter market exclusivity for Orphan Medicinal Products and enhanced supply obligations.
-
Clinical Trials Improvement: The EU is launching initiatives to streamline clinical trials, including FAST-EU for faster authorizations and new guidance for public health emergencies, ensuring participant safety while expediting processes.
-
Medical Device Regulation Update: Proposed amendments aim to simplify the oversight of AI medical devices under the MDR/IVDR, reducing administrative burdens while maintaining patient safety—a move supported by several industry groups.
-
Corporate Governance Changes: New regulations under the Corporate Sustainability Due Diligence Directive (CSDDD) and a proposal for an EU Inc. are set to facilitate cross-border business operations and simplify sustainability reporting requirements.
-
Competition Insights: Revised merger guidelines will emphasize resilience and innovation, affecting collaborations in research and supply chains.
-
Data Privacy Intersection: The CJEU ruled that access requests for personal data can be deemed excessive if abused, additionally highlighting the need for harmonized data protection rules under the draft EU Biotech Act for clinical trials.
-
Global Corruption Risks: Transparency International’s recent report indicates rising corruption risks globally, urging the need for strong governance to mitigate these issues.
These developments suggest a dynamic regulatory landscape for life sciences in the EU, balancing innovation with safety, corporate responsibility, and data privacy.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.jdsupra.com/legalnews/q1-2026-life-sciences-law-update-9674967/
